Oxford Nanopore Technologies has raised £29.3m ($38.6m) in new capital and additionally facilitated the sale of £80.2m ($105.9m) in secondary shares, resulting in total gross proceeds of £109.5m ($144.5m).
These funds have been raised internationally and include both new investors and existing shareholders, from the US, Europe and Asia/Pacific.
This brings the total primary investment in Oxford Nanopore to around £480m to date.
Further information on Oxford Nanopore’s fundraising will be made available in due course.
The Company made substantial progress in 2019; from scaling up to population-scale sequencing with PromethION, to accurate, rapid testing in cancer and infectious disease.
USD amounts assume an exchange rate of 1.32 at 31st December 2019.
